The estimated Net Worth of Steven Reichling is at least $237 Tausend dollars as of 13 March 2023. Steven Reichling owns over 9,438 units of Accelerate Diagnostics Inc stock worth over $236,796 and over the last 10 years Steven sold AXDX stock worth over $0.
Steven has made over 16 trades of the Accelerate Diagnostics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Steven exercised 9,438 units of AXDX stock worth $15,195 on 13 March 2023.
The largest trade Steven's ever made was exercising 123,600 units of Accelerate Diagnostics Inc stock on 8 March 2023 worth over $198,996. On average, Steven trades about 13,737 units every 94 days since 2014. As of 13 March 2023 Steven still owns at least 147,078 units of Accelerate Diagnostics Inc stock.
You can see the complete history of Steven Reichling stock trades at the bottom of the page.
Steven's mailing address filed with the SEC is C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON, AZ, 85714.
Over the last 12 years, insiders at Accelerate Diagnostics Inc have traded over $26,833,308 worth of Accelerate Diagnostics Inc stock and bought 16,366,880 units worth $209,384,489 . The most active insiders traders include Jack W Schuler, Larry N Feinberg und Matthew Strobeck. On average, Accelerate Diagnostics Inc executives and independent directors trade stock every 16 days with the average trade being worth of $132,645. The most recent stock trade was executed by Hany Massarany on 28 June 2024, trading 4,737 units of AXDX stock currently worth $7,627.
accelerate diagnostics, inc. (nasdaq:axdx), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. the company's revolutionary id/ast platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. in addition to the id/ast development pipeline, the company also owns and licenses its proprietary optichem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.
Accelerate Diagnostics Inc executives and other stock owners filed with the SEC include: